GSK2983559 First Time in Human Study

A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03358407

Enrollment

Registered

2017-11-30

Start date

2018-01-11

Completion date

2019-02-19

Last updated

2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

Inflammatory Bowel disease, Pro-drug, Double-blinded, Crossover

Brief summary

This study is the first administration of GSK2983559, a selective receptor interacting protein 2 (RIP2) kinase inhibitor, to humans. This will be randomized, double-blinded (sponsor open) and two part study (A and B). Part A of the study is single ascending dose crossover design with two separate cohorts (1 and 2). In Part A, 9 single dose levels will be explored. In Cohort 1, 10 healthy subjects will randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 4:1 in 5 way cross-over design with 5 treatment periods. In Cohort 2, 8 healthy subjects will be randomized to receive single oral doses of either GSK2983559 or placebo in a ratio of 3:1 in 4 way cross-overs design with 4 treatment periods. In Cohort 2 there will be an additional period (period 5-open label) for assessing GSK2983559 under fed conditions. There will be 48 hours wash-out period between each dose escalation period. Part B is repeat ascending dose sequential group design. It will contain 4 Cohorts of and dosing will be done sequential dosing. Subjects in Part B will receive once daily (QD) dose or twice daily dose (will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A). There will 58 subjects involved in this study. Total duration of Part A will be approximately for 11 Weeks and Part B will be approximately for 15 Weeks.

Interventions

DRUGGSK2983559

GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.

DRUGPlacebo

Placebo oral capsules matching GSK2983559 will be available for subjects.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Male and female subjects between 18 and 65 years of age inclusive, at the time of signing the informed consent. * Volunteers who are overtly healthy as determined by medical evaluation including medical and psychiatric history, physical examination, neurological examination, clinical laboratory tests and cardiac monitoring. * 3Body weight \>= 50 kg (kilogram) and body mass index (BMI) within the range 19-32 kilogram per meter square (kg/m\^2) . * A male subject must agree to use a highly effective contraception during the treatment period and for at least 5 half-lives plus an additional 90 days after the last dose of study treatment and refrain from donating sperm during this period. * A female subject is eligible to participate if she is not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Participants must agree to avoid prolonged Ultraviolet (UV) exposure to natural sunlight without required Ultraviolet A (UVA)/ Ultraviolet B (UVB) protection or tanning beds for the duration of the study.

Exclusion criteria

* History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data. * History or current evidence of febrile seizures, epilepsy, convulsions, significant head injury, or other significant neurologic conditions. * History of clinically significant psychiatric disorders as judged by the investigator. * Any history of suicidal behavior within the past 6 months or any history of attempted suicide in a subject's lifetime. * ALT \>1.5x upper limit of normal (ULN). * Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * History of Gastrointestinal (GI) surgery (with exception of appendectomy) * Average QTc \> 450 millisecond (msec) * Intended use of over-the-counter or prescription medication including herbal medications within 7 days prior to dosing * Live or attenuated vaccine(s) within 30 days of randomization, or plans to receive such vaccines during the study or plans to receive a vaccine within 30 days + 5 half-lives of the last dose of study medication. * Regular alcohol consumption within 6 months prior to the study defined as: An average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 g of alcohol: a half pint (approximately 240 milliliter \[mL\]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits. * Current use or history of regular tobacco- or nicotine-containing products within 6 months prior to screening. Subject must have urinary cotinine levels indicative of non-smoking status at screening visit. * Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day. * Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an investigational study treatment or any other type of medical research. * Subjects with impaired renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation \<= 60 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) estimated by the CKD-EPI equation. * An elevated C-reactive protein (CRP) outside of the normal reference range. * Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. As potential for and magnitude of immunosuppression with this compound is unknown, subjects with presence of hepatitis B core antibody (HBcAb) should also be excluded. Subjects positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded. * A positive pre-study drug/alcohol screen. * A positive test for HIV antibody. * A positive diagnostic TB test at screening defined as a positive QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T-spot test is indeterminate, the subject may have the test repeated once, but they will not be eligible for the study unless the second test is negative. In cases where the QuantiFERON or T-spot test is positive, but a locally-read follow up chest x-ray, shows no evidence of current or previous pulmonary tuberculosis, the subject may be eligible for the study at the discretion of the Investigator and GSK Medical Monitor. * Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study. * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56-day period. * Part A (Food Effect) Cohort: Subject must have no dietary restrictions (e.g., lactose intolerance) or inability to eat a high fat meal.

Design outcomes

Primary

Measure	Time frame	Description
Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Up to 7 weeks	An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.
Part B: Number of Participants With Non-SAEs and SAEs	Up to 11 weeks	An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Non-SAEs and SAEs were planned to be collected.
Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Up to 7 weeks	Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.
Part B: Number of Participants With Worst Case Hematology Parameters of PCI	Up to 11 weeks	Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.
Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Up to 7 weeks	Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Part B: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Up to 11 weeks	Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\ULN U/L, AST(high): \>=2\ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.
Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	Up to 7 weeks	Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.
Part B: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	Up to 11 weeks	Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	1.5, 2, 2.5, 3, 4, 5, 8, 12, 24 and 48 hours post-dose	12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Part B: Number of Participants With Abnormal ECG Findings	Up to 11 weeks	12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.
Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	Up to 7 weeks	DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Part B: Number of Participants With Worst Case DBP and SBP Values of PCI	Up to 11 weeks	DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.
Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	Up to 7 weeks	Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Part B: Number of Participants With Worst Case Respiration Rate Values of PCI	Up to 11 weeks	Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case respiratory rate values of PCI were planned to be evaluated.
Part A: Number of Participants With Worst Case Heart Rate Values of PCI	Up to 7 weeks	Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Part B: Number of Participants With Worst Case Heart Rate Values of PCI	Up to 11 weeks	Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case heart rate values of PCI were planned to be evaluated.
Part A: Number of Participants With Worst Case Body Temperature Values of PCI	Up to 7 weeks	Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.
Part B: Number of Participants With Worst Case Body Temperature Values of PCI	Up to 11 weeks	Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case body temperature values of PCI were planned to be evaluated.
Part A: Number of Participants With Abnormal Findings in Physical Examination	Up to 7 weeks	Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.
Part B: Number of Participants With Abnormal Findings in Physical Examination	Up to 11 weeks	Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.
Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	Baseline (Day 1, Pre-dose), 24 and 48 hours post-dose	Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Part B: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	Baseline and Up to 11 weeks	Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	Baseline (Day 1, Pre-dose), 24 and 48 hours	Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Part B: Change From Baseline in International Normalized Ratio at Indicated Time Points	Baseline and Up to 11 weeks	Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Secondary

Measure	Time frame	Description
Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: AUC From 0 Hours to the Time of Next Dosing AUC(0-tau) for GSK2983559 Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
Part B: AUC(0-tau) for GSK2983559 on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points.
Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: AUC(0-tau) for GSK2668176 (Active Moiety of GSK2983559) on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-tau) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: Cmax for GSK2983559 Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure Cmax at indicated time-points.
Part B: Cmax for GSK2983559 on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure Cmax at indicated time-points.
Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: Cmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure Cmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: Tmax for GSK2983559 Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure Tmax at indicated time-points.
Part B: Tmax for GSK2983559 on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure Tmax at indicated time-points.
Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: Tmax for GSK2668176 (Active Moiety of GSK2983559) on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure Tmax at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: T1/2 for GSK2983559 Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure T1/2 at indicated time-points.
Part B: T1/2 for GSK2983559 on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure T1/2 at indicated time-points.
Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: T1/2 for GSK2668176 (Active Moiety of GSK2983559) on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure T1/2 at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: Accumulation Ratio of GSK2983559	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1.
Part B: Accumulation Ratio of GSK2668176 (Active Moiety of GSK2983559)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC (0-t) for GSK2983559 in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.
Part A (Cohort 2): AUC(0-t) for GSK2983559 in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.
Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Cmax for GSK2983559 in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.
Part A (Cohort 2): Cmax for GSK2983559 in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.
Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Tmax for GSK2983559 in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.
Part A (Cohort 2): Tmax for GSK2983559 in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): T1/2 for GSK2983559 in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4	Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-t) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 2): AUC(0-inf) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 2): Cmax for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): T1/2 for GSK2983559 in Fed Condition (Period 5)	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5	Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.
Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 2): T1/2 for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 2): Tmax for GSK2983559	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.
Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)	Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.
Part B: AUC(0-t) for GSK2983559 Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
Part B: AUC(0-t) for GSK2983559 on Day 14	Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points.
Part B: AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) Following Single Dose on Day 1	Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in each period	Blood samples were planned to be collected to measure AUC(0-t) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Countries

United Kingdom

Participant flow

Recruitment details

This was a 2-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2983559 in healthy participants. The study was terminated early due to non-clinical toxicology findings and reduced safety margins. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Pre-assignment details

A total of 85 participants were screened, of them, 54 participants were screen failures and 31 participants were enrolled and received study treatment in Part A. The study was terminated during Cohort 2 of Part A, hence no participants were enrolled in period 3, 4 and 5 (Cohort 2) of Part A and in Part B.

Participants by arm

Arm	Count
Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg Participants (Par.) received oral single dose of placebo matching GSK2983559 (GSK) in treatment period 1 followed by 4 milligram (mg) GSK2983559 in treatment period 2 followed by 10 mg GSK2983559 in treatment period 3 followed by 30 mg GSK2983559 in treatment period 4 followed by 100 mg GSK2983559 in treatment period 5. There was a washout period of at least 48-hours between 2 periods. There was a follow up (FU) visit after 14 days of last period.	2
Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg Participants received oral single dose of 2 mg GSK2983559 in treatment period 1 followed by placebo matching GSK2983559 in treatment period 2 followed by 10 mg GSK2983559 in treatment period 3 followed by 30 mg GSK2983559 in treatment period 4 followed by 100 mg GSK2983559 in treatment period 5. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period.	2
Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg Participants received oral single dose of 2 mg GSK2983559 in treatment period 1 followed by 4 mg GSK2983559 in treatment period 2 followed by placebo matching GSK2983559 in treatment period 3 followed by 30 mg GSK2983559 in treatment period 4 followed by 100 mg GSK2983559 in treatment period 5. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period.	3
Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg Participants received oral single dose of 2 mg GSK2983559 in treatment period 1 followed by 4 mg GSK2983559 in treatment period 2 followed by 10 mg GSK2983559 in treatment period 3 followed by placebo matching GSK2983559 in treatment period 4 followed by 100 mg GSK2983559 in treatment period 5. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period.	2
Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo Participants received oral single dose of 2 mg GSK2983559 in treatment period 1 followed by 4 mg GSK2983559 in treatment period 2 followed by 10 mg GSK2983559 in treatment period 3 followed by 30 mg GSK2983559 in treatment period 4 followed by placebo matching GSK2983559 in treatment period 5. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period.	3
Part A-Cohort 2: Placebo/GSK 400mg Participants were administered oral single dose of placebo matching GSK2983559 in treatment period 1 followed by 400 mg GSK2983559 in treatment period 2. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period. The periods 3, 4, and 5 were planned but no participants were enrolled in those periods due to early terminated of study. The study was terminated during period 2 of Part A-Cohort 2.	6
Part A-Cohort 2: GSK 200mg/ Placebo Participants were administered oral single dose of 200 mg GSK2983559 in treatment period 1 followed by placebo matching GSK2983559 in treatment period 2. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period. The periods 3, 4, and 5 were planned but no participants were enrolled in those periods due to early terminated of study. The study was terminated during period 2 of Part A-Cohort 2.	4
Part A-Cohort 2: GSK 200mg/GSK 400mg Participants were administered oral single dose of 200 mg GSK2983559 in treatment period 1 followed by 400 mg GSK2983559 in treatment period 2. There was a washout period of at least 48-hours between 2 periods. There was a follow up visit after 14 days of last period. The periods 3, 4, and 5 were planned but no participants were enrolled in those periods due to early terminated of study. The study was terminated during period 2 of Part A-Cohort 2.	9
Part B: Placebo Participants were planned to be administered placebo matching GSK2983559 either once daily or twice daily. Though, no participants were enrolled in Part B since the study was terminated during Part A due to non-clinical toxicology findings and reduced safety margins.	0
Part B: GSK2983559 Participants were planned to be administered GSK2983559 in repeat ascending dose sequential period either once daily or twice daily based upon the pharmacokinetic, safety and tolerability observed in Part A. Though, no participants were enrolled in Part B since the study was terminated during Part A due to non-clinical toxicology findings and reduced safety margins.	0
Total	31

Withdrawals & dropouts

Period	Reason	FG002	FG004	FG005	FG006	FG007
P1:PartA-Cohort2(4days)+Washout(48hours)	Adverse Event	0	0	1	0	2
P1:PartA-Cohort2(4days)+Washout(48hours)	Physician Decision	0	0	1	0	1
P1:PartA-Cohort2(4days)+Washout(48hours)	Withdrawal by Subject	0	0	1	1	0
P2:PartA-Cohort1(4days)+Washout(48hours)	Adverse Event	1	0	0	0	0
P2:PartA-Cohort2(4days)+Followup(14days)	Study closed/terminated	0	0	3	3	6
P4:PartA-Cohort1(4days)+Washout(48hours)	Withdrawal by Subject	0	1	0	0	0

Baseline characteristics

Characteristic	Part A-Cohort 1: Placebo/GSK 4mg/GSK 10mg/GSK 30mg/GSK 100mg	Part A-Cohort 1: GSK 2mg/Placebo/GSK 10mg/GSK 30mg/GSK 100mg	Part A-Cohort 1: GSK 2mg/GSK 4mg/Placebo/GSK 30mg/GSK 100mg	Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/Placebo/GSK 100mg	Part A-Cohort 1: GSK 2mg/GSK 4mg/GSK 10mg/GSK 30mg/Placebo	Part A-Cohort 2: Placebo/GSK 400mg	Part A-Cohort 2: GSK 200mg/ Placebo	Part A-Cohort 2: GSK 200mg/GSK 400mg	Total	Part B: GSK2983559	Part B: Placebo
Age, Continuous	38.0 Years STANDARD_DEVIATION 11.31	46.0 Years STANDARD_DEVIATION 14.14	52.7 Years STANDARD_DEVIATION 11.85	45.5 Years STANDARD_DEVIATION 13.44	59.3 Years STANDARD_DEVIATION 4.73	42.3 Years STANDARD_DEVIATION 10.5	33.8 Years STANDARD_DEVIATION 7.04	42.8 Years STANDARD_DEVIATION 11.89	44.2 Years STANDARD_DEVIATION 11.73	—	—
Race/Ethnicity, Customized Asian - Central/South Asian Heritage	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	1 Participants	0 Participants	3 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Black or African American	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized White - White/Caucasian/European Heritage	2 Participants	2 Participants	3 Participants	1 Participants	3 Participants	5 Participants	2 Participants	9 Participants	27 Participants	0 Participants	0 Participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	2 Participants	2 Participants	3 Participants	2 Participants	3 Participants	6 Participants	4 Participants	9 Participants	31 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk
deaths Total, all-cause mortality	0 / 16	0 / 8	0 / 8	0 / 8	0 / 8	0 / 8	0 / 9	0 / 9
other Total, other adverse events	6 / 16	2 / 8	2 / 8	1 / 8	1 / 8	2 / 8	4 / 9	4 / 9
serious Total, serious adverse events	0 / 16	0 / 8	0 / 8	0 / 8	0 / 8	0 / 8	0 / 9	0 / 9

Outcome results

Primary

Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

Blood samples were collected to evaluate activated partial thromboplastin time (APTT) and prothrombin time (PT) at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours post-dose

Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: Placebo	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	0.4 Seconds	Standard Deviation 3.35
Part A: Placebo	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	0.5 Seconds	Standard Deviation 2.99
Part A: Placebo	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	0.1 Seconds	Standard Deviation 0.62
Part A: Placebo	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	-0.1 Seconds	Standard Deviation 0.34
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	0.0 Seconds	Standard Deviation 0.53
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	-0.3 Seconds	Standard Deviation 2.66
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	0.8 Seconds	Standard Deviation 1.83
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	0.3 Seconds	Standard Deviation 0.46
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	2.9 Seconds	Standard Deviation 2.85
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	-0.3 Seconds	Standard Deviation 0.46
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	0.5 Seconds	Standard Deviation 3.07
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	-0.3 Seconds	Standard Deviation 0.46
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	-0.7 Seconds	Standard Deviation 1.8
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	0.8 Seconds	Standard Deviation 2.38
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	0.1 Seconds	Standard Deviation 0.69
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	0.1 Seconds	Standard Deviation 0.64
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	-0.1 Seconds	Standard Deviation 0.35
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	-0.1 Seconds	Standard Deviation 0.35
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	0.0 Seconds	Standard Deviation 1.69
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	1.0 Seconds	Standard Deviation 1.77
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	0.1 Seconds	Standard Deviation 0.35
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	0.1 Seconds	Standard Deviation 0.35
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	2.3 Seconds	Standard Deviation 2.71
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	1.0 Seconds	Standard Deviation 2.56
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	-0.4 Seconds	Standard Deviation 1.51
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	-1.3 Seconds	Standard Deviation 6.1
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	-0.2 Seconds	Standard Deviation 1.48
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	-3.0 Seconds	Standard Deviation 6.37
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 48 hours, n=16,8,8,8,8,8,8,9	-2.4 Seconds	Standard Deviation 2.96
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 24 hours, n=16,8,8,7,8,8,9,9	0.0 Seconds	Standard Deviation 0.87
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	PT, 48 hours, n=16,8,8,8,8,8,8,9	0.1 Seconds	Standard Deviation 0.93
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points	APTT, 24 hours, n=16,8,8,7,8,8,9,9	-1.2 Seconds	Standard Deviation 2.11

Primary

Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points

Blood samples were collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame: Baseline (Day 1, Pre-dose), 24 and 48 hours

Arm	Measure	Group	Value (MEAN)	Dispersion
Part A: Placebo	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.018 Ratio	Standard Deviation 0.0248
Part A: Placebo	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	0.001 Ratio	Standard Deviation 0.0496
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	0.013 Ratio	Standard Deviation 0.0345
Part A-Cohort 1: GSK2983559 2 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	0.010 Ratio	Standard Deviation 0.0278
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	-0.005 Ratio	Standard Deviation 0.0404
Part A-Cohort 1: GSK2983559 4 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.021 Ratio	Standard Deviation 0.0356
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.009 Ratio	Standard Deviation 0.0405
Part A-Cohort 1: GSK2983559 10 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	-0.019 Ratio	Standard Deviation 0.043
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	-0.002 Ratio	Standard Deviation 0.0282
Part A-Cohort 1: GSK2983559 30 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.024 Ratio	Standard Deviation 0.0233
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	0.017 Ratio	Standard Deviation 0.0354
Part A-Cohort 1: GSK2983559 100 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	0.020 Ratio	Standard Deviation 0.0293
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	-0.028 Ratio	Standard Deviation 0.1204
Part A-Cohort 2: GSK2983559 200 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.035 Ratio	Standard Deviation 0.1165
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	48 hours, n=16,8,8,8,8,8,8,9	-0.020 Ratio	Standard Deviation 0.0738
Part A-Cohort 2: GSK2983559 400 mg	Part A: Change From Baseline in International Normalized Ratio at Indicated Time Points	24 hours, n=16,8,8,7,8,8,9,9	-0.019 Ratio	Standard Deviation 0.0752

Primary

Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings

12-lead ECGs were obtained using an ECG machine. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame: 1.5, 2, 2.5, 3, 4, 5, 8, 12, 24 and 48 hours post-dose

Population: Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 3 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 5 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 5 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A: Placebo	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 3 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 3 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 5 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 5 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 3 hours, n=6,0,0,0,0,0,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 8 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 1.5 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 5 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 5 hours, n=6,0,0,0,0,0,9,9	2 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 3 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 4 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 1.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 2.5 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 48 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 3 hours, n=6,0,0,0,0,0,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 2.5 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal NCS, 24 hours, n=16,8,8,8,8,8,9,9	1 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 24 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 8 hours, n=16,8,8,8,8,8,9,9	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings	Abnormal CS, 12 hours, n=16,8,8,8,8,8,9,9	0 Participants

Primary

Part A: Number of Participants With Abnormal Findings in Physical Examination

Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. This analysis was not planned and data was not collected and not captured in the database.

Time frame: Up to 7 weeks

Population: Safety Population. This analysis was not planned and data was not collected and not captured in the database. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Primary

Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE was defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

Time frame: Up to 7 weeks

Population: Safety Population comprised of all randomized participants who received at least one dose of study treatment. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A: Placebo	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	6 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	2 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	2 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	1 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	1 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	2 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	4 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Non Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)	Non-SAEs	4 Participants

Primary

Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

Urine samples were collected to assess glucose, ketones, occult blood and protein by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters glucose, ketones, occult blood and protein were categorized as 'any increase from Baseline', which imply any increase in their concentrations in the urine sample. Baseline was defined as latest predose (Day 1) assessment with a non-missing value.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method	0 Participants

Primary

Part A: Number of Participants With Worst Case Body Temperature Values of PCI

Body temperature was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=35.5 degrees Celsius (lower) and \>=37.8 degrees Celsius (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	1 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	15 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	7 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	1 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	6 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	2 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	8 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	1 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To low	2 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Body Temperature Values of PCI	To within range or no change	7 Participants

Primary

Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

Clinical chemistry parameters included alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), calcium, creatinine, glucose, potassium, sodium and total bilirubin (T.bil). PCI ranges were: ALT, AST, ALP (high): \>=2\*Upper limit of Normal(ULN) units per liter(U/L), albumin(low): 30 g/L, calcium: \<2(low) or \>2.75 millimoles per liter (mmol/L)(high), creatinine (high): increase from Baseline \>44.2 micromoles per liter(µmol/L), glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and T.bil(high): \>=1.5\*ULN (µmol/L). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Only those clinical chemistry parameters with PCI values have been presented. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	1 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	15 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	8 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALT, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Calcium, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	T.bil, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Potassium, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Creatinine, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Sodium, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	ALP, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	AST, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Albumin, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI	Glucose, To low	0 Participants

Primary

Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI

DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 millimeters of mercury (mmHg) (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	16 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	DBP, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Values of PCI	SBP, To within range or no change	9 Participants

Primary

Part A: Number of Participants With Worst Case Heart Rate Values of PCI

Heart rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<40 beats per minute (lower) and \>110 beats per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	16 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	7 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	1 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	1 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Heart Rate Values of PCI	To high	0 Participants

Primary

Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)

Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and white blood cells (WBCs) count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Only those hematology parameters with PCI values have been presented.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	1 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	15 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	16 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	1 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	8 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Lymphocytes, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hematocrit, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To within range or no change	9 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Platelet count, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Hemoglobin, To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	WBC count, To high	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Hematology Parameters of Potential Clinical Importance (PCI)	Total Neutrophils, To within range or no change	9 Participants

Primary

Part A: Number of Participants With Worst Case Respiration Rate Values of PCI

Respiration rate was measured in semi-supine position after 5 minutes rest. PCI ranges included \<=8 breaths per minute (lower) and \>=20 breaths per minute (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category.

Time frame: Up to 7 weeks

Population: Safety Population. Data is presented treatment-wise. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part A: Placebo	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	4 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A: Placebo	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	12 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	1 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 2 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	7 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	6 Participants
Part A-Cohort 1: GSK2983559 4 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	2 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	0 Participants
Part A-Cohort 1: GSK2983559 10 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	1 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	7 Participants
Part A-Cohort 1: GSK2983559 30 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	1 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	7 Participants
Part A-Cohort 1: GSK2983559 100 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	2 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 2: GSK2983559 200 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	7 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To within range or no change	8 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To low	0 Participants
Part A-Cohort 2: GSK2983559 400 mg	Part A: Number of Participants With Worst Case Respiration Rate Values of PCI	To high	1 Participants

Primary

Part B: Change From Baseline in Activated Partial Thromboplastin Time and Prothrombin Time at Indicated Time Points

Blood samples were planned to be collected to evaluate PTT and PT at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame: Baseline and Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Change From Baseline in International Normalized Ratio at Indicated Time Points

Blood samples were planned to be collected to evaluate international normalized ratio at indicated time points. Baseline was defined as latest pre-dose (Day 1) assessment with a non-missing value. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame: Baseline and Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Abnormal ECG Findings

12-lead ECGs were planned to be obtained using an ECG machine. Abnormal ECG findings were categorized as CS and NCS abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Participants with any abnormal ECG findings were planned to be evaluated.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Abnormal Findings in Physical Examination

Physical examinations included assessment of the skin, cardiovascular, respiratory, and gastrointestinal systems. Data was not collected and not captured in the database.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Non-SAEs and SAEs

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method

Urine analysis included assessment of glucose, ketones, occult blood and protein by dipstick method. The dipstick test gives results in a semi-quantitative manner. Baseline was defined as latest predose (Day 1) assessment with a non-missing value. Participants with worst case any increase in urinalysis results post-Baseline relative to Baseline were planned to be collected.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Body Temperature Values of PCI

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Clinical Chemistry Parameters of PCI

Clinical chemistry parameters included ALT, albumin, alkaline phosphatase, AST, calcium, creatinine, glucose, potassium, sodium and total bilirubin. PCI ranges were ALT(high): \>=2\*ULN U/L, albumin(low): 30 g/L, alkaline phosphatase(high): \>=2\*ULN U/L, AST(high): \>=2\*ULN U/L, calcium: \<2(low) or \>2.75 mmol/L (high), creatinine (high): increase from Baseline \>44.25 µmol/L, glucose: \<3(low) or \>9 mmol/L(high), potassium: \<3(low) or \>5.5 mmol/L(high), sodium: \<130(low) or \>150 mmol/L(high) and total bilirubin(high): \>=1.5\*ULN (µmol/L). Participants with worst case clinical chemistry parameters of PCI were planned to be collected.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case DBP and SBP Values of PCI

DBP and SBP were measured in semi-supine position after 5 minutes rest. PCI ranges included DBP: \<45 mmHg (lower) and \>100 mmHg (higher) and SBP: \<85 mmHg (lower) and \>160 mmHg (higher). Participants were counted in the worst case category that their value changes to (low, or within range or no change, or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case DBP and SBP values of PCI were planned to be evaluated.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Heart Rate Values of PCI

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Hematology Parameters of PCI

Hematology parameters included hematocrit, hemoglobin, lymphocytes, platelet counts, total neutrophils and WBC count. PCI ranges were: hematocrit (high: \>0.54 proportion of red blood cells in blood and low: change from baseline\<0.0075); hemoglobin (high: \>180 grams per liter \[g/L\] and low: change from baseline\<25 g/L); lymphocytes (low: \<0.8 Giga cells/L); platelet count (low: \<100 Giga cells/L and high: \>550 Giga cells/L); neutrophil count (low: \<1.5 Giga cells/L); white blood cell count (low: \<3 Giga cells/L and high: \>20 Giga cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high) unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the 'To within Range or No Change' category. Participants with worst case hematology parameters of PCI were planned to be collected.

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Primary

Part B: Number of Participants With Worst Case Respiration Rate Values of PCI

Time frame: Up to 11 weeks

Population: Safety Population. Data was not collected as no participants were enrolled in Part B due to study termination during Part A.

Secondary

Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population comprised of all participants in the safety population who had at least 1 non-missing pharmacokinetic assessment. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	NA Hours*nanogram per milliliter	—
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	NA Hours*nanogram per milliliter	—
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	NA Hours*nanogram per milliliter	—
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	1.4088 Hours*nanogram per milliliter	Geometric Coefficient of Variation 38.9
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2983559	7.2488 Hours*nanogram per milliliter	Geometric Coefficient of Variation 63.5

Secondary

Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	104.28 Hours*nanogram per milliliter	Geometric Coefficient of Variation 19.4
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	257.28 Hours*nanogram per milliliter	Geometric Coefficient of Variation 36
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	405.39 Hours*nanogram per milliliter	Geometric Coefficient of Variation 16
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	911.53 Hours*nanogram per milliliter	Geometric Coefficient of Variation 17.1
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	2860.23 Hours*nanogram per milliliter	Geometric Coefficient of Variation 43

Secondary

Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	96.7389 Hours*nanogram per milliliter	Geometric Coefficient of Variation 19.3
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	250.6231 Hours*nanogram per milliliter	Geometric Coefficient of Variation 36.3
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	390.3911 Hours*nanogram per milliliter	Geometric Coefficient of Variation 17.5
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	889.6956 Hours*nanogram per milliliter	Geometric Coefficient of Variation 17.2
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	2760.8122 Hours*nanogram per milliliter	Geometric Coefficient of Variation 41.3

Secondary

Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)
Part A: Placebo	Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	NA Hours*nanogram per milliliter
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	NA Hours*nanogram per milliliter
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	NA Hours*nanogram per milliliter
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	NA Hours*nanogram per milliliter
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): AUC From Time Zero to Infinity (AUC[0-inf]) for GSK2983559	NA Hours*nanogram per milliliter

Secondary

Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	10.4980 Nanograms per milliliter	Geometric Coefficient of Variation 34.5
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	25.9587 Nanograms per milliliter	Geometric Coefficient of Variation 38.6
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	38.4341 Nanograms per milliliter	Geometric Coefficient of Variation 35.5
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	93.8714 Nanograms per milliliter	Geometric Coefficient of Variation 19.5
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Cmax for GSK2668176 (Active Moiety of GSK2983559)	305.9839 Nanograms per milliliter	Geometric Coefficient of Variation 33

Secondary

Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	NA Nanograms per milliliter	—
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	NA Nanograms per milliliter	—
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	0.2291 Nanograms per milliliter	Geometric Coefficient of Variation 12.4
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	0.4034 Nanograms per milliliter	Geometric Coefficient of Variation 37.3
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Maximum Plasma Concentration (Cmax) for GSK2983559	1.1937 Nanograms per milliliter	Geometric Coefficient of Variation 40.2

Secondary

Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	7.044 Hours	Geometric Coefficient of Variation 33.2
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	8.304 Hours	Geometric Coefficient of Variation 26.9
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	9.649 Hours	Geometric Coefficient of Variation 26.9
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	8.717 Hours	Geometric Coefficient of Variation 23
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	9.799 Hours	Geometric Coefficient of Variation 24.7

Secondary

Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)
Part A: Placebo	Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Terminal Elimination Half-life (T1/2) for GSK2983559	NA Hours

Secondary

Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEDIAN)
Part A: Placebo	Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	4.500 Hours
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	4.005 Hours
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Time to Cmax (Tmax) for GSK2983559	4.000 Hours

Secondary

Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (MEDIAN)
Part A: Placebo	Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	3.000 Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	2.758 Hours
Part A-Cohort 1: GSK2983559 4 mg	Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	4.006 Hours
Part A-Cohort 1: GSK2983559 10 mg	Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	4.037 Hours
Part A-Cohort 1: GSK2983559 30 mg	Part A (Cohort 1): Tmax for GSK2668176 (Active Moiety of GSK2983559)	3.000 Hours

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	2717.46 Hours*nanogram per milliliter	Geometric Coefficient of Variation 57.5
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559)	2950.11 Hours*nanogram per milliliter	Geometric Coefficient of Variation 38.5

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2983559

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)
Part A: Placebo	Part A (Cohort 2): AUC(0-inf) for GSK2983559	NA Hours*nanogram per milliliter
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): AUC(0-inf) for GSK2983559	NA Hours*nanogram per milliliter

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-inf) in fasted condition (Period 4) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-inf) for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-inf) in fed condition (Period 5) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	2608.4326 Hours*nanogram per milliliter	Geometric Coefficient of Variation 59.7
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559)	2857.1378 Hours*nanogram per milliliter	Geometric Coefficient of Variation 39.9

Secondary

Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-t) for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-t) for GSK2983559

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): AUC(0-t) for GSK2983559	8.1765 Hours*nanogram per milliliter	Geometric Coefficient of Variation 61.7
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): AUC(0-t) for GSK2983559	5.9980 Hours*nanogram per milliliter	Geometric Coefficient of Variation 67.3

Secondary

Part A (Cohort 2): AUC (0-t) for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure AUC(0-t) in fasted condition (Period 4) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): AUC(0-t) for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure AUC(0-t) in fed condition (Period 5) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)	314.2321 Nanograms per milliliter	Geometric Coefficient of Variation 113.3
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559)	351.0316 Nanograms per milliliter	Geometric Coefficient of Variation 68.9

Secondary

Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Cmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Cmax for GSK2983559

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): Cmax for GSK2983559	1.3931 Nanograms per milliliter	Geometric Coefficient of Variation 69.3
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): Cmax for GSK2983559	1.1244 Nanograms per milliliter	Geometric Coefficient of Variation 70

Secondary

Part A (Cohort 2): Cmax for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Cmax in fasted condition (Period 4) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Cmax for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Cmax in fed condition (Period 5) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Part A: Placebo	Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	10.480 Hours	Geometric Coefficient of Variation 20.4
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559)	9.526 Hours	Geometric Coefficient of Variation 25.6

Secondary

Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): T1/2 for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): T1/2 for GSK2983559

Blood samples were collected to measure T1/2 at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (GEOMETRIC_MEAN)
Part A: Placebo	Part A (Cohort 2): T1/2 for GSK2983559	NA Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): T1/2 for GSK2983559	NA Hours

Secondary

Part A (Cohort 2): T1/2 for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure T1/2 in fasted condition (Period 4) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): T1/2 for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure T1/2 in fed condition (Period 5) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (MEDIAN)
Part A: Placebo	Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)	3.083 Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559)	3.500 Hours

Secondary

Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Tmax for GSK2668176 (Active Moiety of GSK2983559) in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Tmax for GSK2983559

Blood samples were collected to measure Tmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods.

Time frame: Pre-dose and at 15 and 30 minutes; 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period

Population: Pharmacokinetic Population

Arm	Measure	Value (MEDIAN)
Part A: Placebo	Part A (Cohort 2): Tmax for GSK2983559	3.506 Hours
Part A-Cohort 1: GSK2983559 2 mg	Part A (Cohort 2): Tmax for GSK2983559	4.000 Hours

Secondary

Part A (Cohort 2): Tmax for GSK2983559 in Fasted Condition (Period 4)

Blood samples were planned to be collected to measure Tmax in fasted condition (Period 4) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 4

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 4 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part A (Cohort 2): Tmax for GSK2983559 in Fed Condition (Period 5)

Blood samples were planned to be collected to measure Tmax in fed condition (Period 5) at indicated time-points.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose in Period 5

Population: Pharmacokinetic Population. Data was not collected as no participants were enrolled in period 5 of cohort 2 of Part A as the study was terminated during period 2 of cohort 2 of Part A.

Secondary

Part B: Accumulation Ratio of GSK2668176 (Active Moiety of GSK2983559)

Blood samples were planned to be collected to measure accumulation ratio at indicated time-points. Accumulation ratio was to be calculated as ratio of AUC(0-tau) at Day 14 to AUC(0-tau) at Day 1. GSK2668176 is the active moiety of pro-drug GSK2983559.

Time frame: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours post-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose in each period